1456PPhase IV, open-label, multicentre trial of afatinib in patients (pts) aged ≥70 yrs with NSCLC harbouring common (Del19/L858R) EGFR mutations: Preliminary results. (23rd October 2018) - Reckamp, K L; Gilman, P; Halmos, B; Jahanzeb, M; McCann, J; Paripati, H; Seneviratne, L C; Wallace, J A; Rueter, B; Esler, A; Dowling, E; Koczywas, M